Menopause Symptoms: Drugs That Cause or Treat Them

What Causes Menopause Symptoms?

Menopause symptoms arise primarily from declining ovarian estrogen production, which destabilizes thermoregulatory circuits in the hypothalamus, thins genitourinary mucosa, and disrupts serotonin and norepinephrine signaling. The median age at natural menopause in the United States is 51.4 years, though perimenopause can begin 4 to 8 years earlier [1].

The core vasomotor symptoms (hot flashes and night sweats) stem from a narrowed thermoneutral zone in the hypothalamus. Research published in The Lancet identified hypertrophied kisspeptin/neurokinin B/dynorphin (KNDy) neurons as the central mediators: when estrogen drops, neurokinin B signaling surges and destabilizes the body's internal thermostat [2]. This finding opened a direct drug target, and it explains why both estrogen replacement and NK3 receptor blockade work.

Beyond vasomotor flares, falling estradiol levels affect sleep architecture, mood regulation, bone turnover, vaginal pH, and collagen synthesis. The result is a symptom cluster that can include insomnia, anxiety, joint stiffness, dyspareunia, and accelerated bone loss. A longitudinal analysis from the Study of Women's Health Across the Nation (SWAN) found that the median duration of frequent vasomotor symptoms is 7.4 years, far longer than the "few years" traditionally quoted [3]. That duration matters because it shapes how long pharmacotherapy may be needed.

Certain medications can precipitate or intensify these same symptoms by lowering circulating estrogen or interfering with hypothalamic thermoregulation. The sections below separate the drugs that relieve menopause symptoms from those that cause them.

Hormone Therapy: The First-Line Standard

Systemic estrogen remains the single most effective pharmacotherapy for vasomotor symptoms. A 2004 Cochrane review of 24 randomized trials (N=3,329) found that oral or transdermal estrogen reduced hot flash frequency by 75% and severity by 87% compared with placebo [4].

Current options include oral conjugated equine estrogens (CEE) 0.3 to 0.625 mg/day, oral micronized estradiol 0.5 to 1 mg/day, and transdermal estradiol patches delivering 0.025 to 0.05 mg/day. The 2022 position statement from The Menopause Society (formerly NAMS) endorses initiating hormone therapy (HT) in symptomatic women younger than 60 or within 10 years of menopause onset, when benefits generally outweigh risks [5]. Women with an intact uterus require concurrent progestogen to prevent endometrial hyperplasia.

Transdermal estradiol avoids hepatic first-pass metabolism. That distinction matters clinically: a nested case-control study within the UK General Practice Research Database (N=80,396 cases) found that transdermal estradiol at doses <0.05 mg/day carried no excess venous thromboembolism risk, while oral estrogen raised risk by approximately 40% [6].

For women who cannot or prefer not to use estrogen, the combination of bazedoxifene 20 mg with conjugated estrogens 0.45 mg (Duavee) offers endometrial protection through a selective estrogen receptor modulator (SERM) rather than a progestogen, which may suit women who experience breast tenderness or mood changes on progesterone [7].

Dr. Stephanie Faubion, Medical Director of The Menopause Society, has stated: "Hormone therapy remains the most effective treatment for menopausal vasomotor symptoms and should be considered the first-line therapy for women without contraindications" [5].

Non-Hormonal Prescription Treatments for Hot Flashes

Not every woman is a candidate for estrogen. Breast cancer survivors, women with a history of venous thromboembolism, and those with active liver disease may need non-hormonal alternatives. Several classes of drugs have demonstrated efficacy in randomized trials.

Fezolinetant (Veozah). Approved by the FDA in May 2023, fezolinetant is a selective neurokinin 3 (NK3) receptor antagonist that works directly on the KNDy neuron pathway. In the phase 3 SKYLIGHT 1 trial (N=501), fezolinetant 45 mg/day reduced moderate-to-severe vasomotor symptom frequency by 61.3% at week 12, compared with 42.4% for placebo (P<0.001) [8]. The most common adverse effect is hepatotoxicity, requiring liver function testing before and during treatment. This drug represents a genuine mechanistic advance over repurposed antidepressants.

Paroxetine 7.5 mg (Brisdelle). The only SSRI with FDA approval specifically for vasomotor symptoms. A randomized trial (N=1,184) demonstrated a mean reduction of 1.66 hot flashes per day versus 1.37 for placebo at 12 weeks [9]. The effect size is modest compared with HT, but paroxetine offers meaningful relief for women who cannot take estrogen.

Venlafaxine and desvenlafaxine. The SNRI venlafaxine at 75 mg/day reduced hot flash scores by 61% in a placebo-controlled trial in breast cancer survivors (N=229) [10]. Desvenlafaxine 100 to 150 mg showed similar effects. These are used off-label.

Gabapentin. Gabapentin 900 mg/day reduced hot flash frequency by 45% versus 29% for placebo in a 12-week trial (N=420) [11]. It is particularly useful when insomnia co-occurs with vasomotor symptoms because of its sedating profile.

Oxybutynin. A randomized crossover trial (N=150) found that extended-release oxybutynin 15 mg/day reduced hot flashes by 72% compared with 28% for placebo, an effect size rivaling some hormonal preparations [12]. Dry mouth is the main limitation.

Genitourinary Syndrome of Menopause: Targeted Drug Options

Genitourinary syndrome of menopause (GSM) affects up to 84% of postmenopausal women and, unlike hot flashes, does not spontaneously resolve. It worsens over time without treatment. The hallmark complaints are vaginal dryness, burning, irritation, dyspareunia, and recurrent urinary tract infections [13].

Low-dose vaginal estrogen is the standard of care for GSM when systemic therapy is not needed. A 10-mcg estradiol vaginal tablet, a 7.5-mcg/24-hour estradiol ring (Estring), or a 0.5 g conjugated estrogen cream applied two to three times weekly restores vaginal epithelium with minimal systemic absorption. Serum estradiol levels typically remain in the postmenopausal range (<20 pg/mL). The 2020 Cochrane review of 30 trials confirmed that all local estrogen formulations are similarly effective and superior to placebo [14].

Ospemifene (Osphena) is an oral SERM approved for moderate-to-severe dyspareunia from GSM. In the key trial (N=826), ospemifene 60 mg/day improved vaginal dryness scores significantly versus placebo at 12 weeks, with hot flashes as the most common side effect (7.5% vs 2.6%) [15].

Prasterone (Intrarosa) is an intravaginal dehydroepiandrosterone (DHEA) insert dosed at 6.5 mg nightly. It converts locally to both estrogen and androgen metabolites. A phase 3 trial (N=558) showed significant improvement in dyspareunia and vaginal cell maturation index versus placebo at 12 weeks [16].

Dr. JoAnn Pinkerton, past executive director of The Menopause Society, noted: "Women should know that genitourinary symptoms of menopause are progressive, common, and treatable. There is no reason to suffer in silence" [13].

Drugs That Cause or Worsen Menopause Symptoms

Several medication classes lower estrogen, suppress ovarian function, or interfere with thermoregulation, producing symptoms indistinguishable from natural menopause. Recognizing these drug-induced triggers is just as important as choosing the right treatment.

Aromatase inhibitors (AIs). Anastrozole, letrozole, and exemestane block peripheral conversion of androgens to estrogen in postmenopausal breast cancer patients. They suppress already-low estradiol to near-undetectable levels. The ATAC trial (N=9,366) reported that 35.7% of women on anastrozole experienced hot flashes, and 29.4% reported joint stiffness or arthralgia [17]. Vaginal dryness and sexual dysfunction rates also exceeded those on tamoxifen.

GnRH agonists and antagonists. Leuprolide (Lupron), goserelin (Zoladex), and the oral GnRH antagonists elagolix (Orilissa) and relugolix (Myfembree) suppress pituitary gonadotropins, creating a state of medical menopause. This mechanism is used deliberately in endometriosis, uterine fibroids, and prostate cancer. Hot flashes occur in 50 to 80% of patients. Add-back therapy (low-dose estrogen/progestogen) is recommended for elagolix and relugolix to mitigate bone loss and vasomotor symptoms during long-term use [18].

Tamoxifen. A SERM used in estrogen-receptor-positive breast cancer, tamoxifen acts as an estrogen antagonist in the hypothalamus. Hot flashes affect 33 to 70% of users. The NSABP P-1 prevention trial (N=13,388) documented hot flashes in 68% of tamoxifen-treated women versus 48% on placebo [19].

Chemotherapy agents. Alkylating agents such as cyclophosphamide are directly gonadotoxic, causing premature ovarian insufficiency (POI) in premenopausal women. The risk is dose-dependent and age-dependent: women over 40 receiving cyclophosphamide-based regimens face POI rates exceeding 70% [20]. The resulting menopause is often permanent.

Other medications. Certain drugs produce vasomotor-like flushing through non-estrogenic mechanisms. Niacin causes prostaglandin-mediated flushing in up to 70% of users. Calcium channel blockers (amlodipine, nifedipine) can trigger flushing and peripheral edema. Opioid withdrawal induces diaphoresis and temperature dysregulation that mimics night sweats.

How to Choose Between Hormonal and Non-Hormonal Approaches

Treatment selection hinges on three variables: symptom severity, time since menopause, and individual contraindications. The 2023 Endocrine Society clinical practice guideline recommends systemic estrogen as first-line for moderate-to-severe vasomotor symptoms in appropriate candidates and lists fezolinetant, SSRIs/SNRIs, gabapentin, and oxybutynin as alternatives when hormones are contraindicated [21].

For women within 10 years of menopause with vasomotor symptoms and no contraindications, transdermal estradiol at the lowest effective dose is the approach with the strongest benefit-risk ratio. The WHI reanalysis stratified by age showed that HT initiated in women aged 50 to 59 was associated with a non-significant reduction in all-cause mortality (hazard ratio 0.69, 95% CI 0.44 to 1.07) [22]. That finding contrasts sharply with the early panic over the 2002 WHI headlines, which reported outcomes driven largely by women starting HT at ages 63 and older.

For breast cancer survivors, fezolinetant's lack of estrogenic activity makes it a strong candidate, though long-term safety data beyond 52 weeks are still accruing. Venlafaxine and gabapentin remain well-studied alternatives in this population.

Women whose primary complaint is GSM without systemic vasomotor symptoms generally need only local vaginal therapy, not systemic HT. Vaginal estrogen, ospemifene, and prasterone each address the local estrogen deficit.

Duration of therapy depends on symptom persistence. Because SWAN data show median vasomotor symptom duration of 7.4 years, the old recommendation to limit HT to "the shortest duration" has softened. The 2022 Menopause Society statement supports individualized duration decisions with periodic reassessment rather than arbitrary time caps [5].

When to Seek Medical Evaluation

Most menopause symptoms are physiologic, but certain patterns warrant urgent assessment. Onset of hot flashes or amenorrhea before age 40 suggests primary ovarian insufficiency and requires hormonal workup including FSH, estradiol, and anti-Mullerian hormone levels. Unscheduled vaginal bleeding more than 12 months after the final menstrual period demands endometrial evaluation to exclude malignancy. Night sweats accompanied by unexplained weight loss, lymphadenopathy, or persistent fevers should prompt consideration of lymphoma, tuberculosis, or pheochromocytoma rather than menopause.

Any woman who starts a new medication and develops vasomotor-like symptoms should discuss the timing with her prescriber. Drug-induced hot flashes from tamoxifen or AIs are common and expected, but management options exist: dose adjustments, concurrent non-hormonal vasomotor therapy, or in selected cases, switching within the drug class.

Monitoring for women on HT should include annual clinical breast examination, mammography per USPSTF guidelines, and periodic reassessment of the benefit-risk balance. Women on fezolinetant require liver function tests at baseline, after 3 months, after 6 months, and after 9 months of therapy [8].

The threshold for seeking help is simple: if menopause symptoms interfere with sleep, work, relationships, or daily function, pharmacotherapy should be discussed. Clinicians can initiate HRT at the first visit when indicated per current guidelines without a mandatory trial of lifestyle measures.